Perioperative toripalimab improves event-free survival in non-small cell lung cancer
1. In patients with resectable stage III non-small cell lung cancer, perioperative toripalimab plus chemotherapy increased rates of tumor and ...
1. In patients with resectable stage III non-small cell lung cancer, perioperative toripalimab plus chemotherapy increased rates of tumor and ...
1. In this phase 1-2 trial involving patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy, ...
1. Chemotherapy appears to be independently associated with reduced pain severity in advanced pancreatic cancer, reinforcing the importance of routine, ...
1. Sequential and upfront treatment of metastatic colorectal cancer (mCRC) with oxaliplatin (OX)-based therapy does not lead to significantly different ...
1. In this randomized controlled trial, administering pegfilgrastim 72 hours after chemotherapy reduced bone pain compared with 24- or 48-hour ...
1. Among patients with previously untreated programmed death-ligand 1 positive, triple-negative breast cancer, first-line sacituzumab govitecan plus pembrolizumab significantly prolonged ...
1. A new WHO analysis finds one in six bacterial infections worldwide is now resistant to standard antibiotics. 2. Resistance ...
1. Royalty Pharma struck a deal worth up to 950 million dollars to buy into Amgen’s DLL3 directed bispecific for ...
1. Progression-free survival and overall survival were significantly greater in the combination therapy group compared to enzalutamide alone. 2. Anemia ...
1. Progression-free survival was significantly greater in retifanlimab compared to placebo. 2. Serious and grade 3 or more adverse events ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.